Edition:
India

NuCana PLC (NCNA.OQ)

NCNA.OQ on NASDAQ Stock Exchange Global Select Market

23.64USD
20 Apr 2018
Change (% chg)

$0.81 (+3.55%)
Prev Close
$22.83
Open
$22.65
Day's High
$24.80
Day's Low
$21.81
Volume
16,018
Avg. Vol
30,192
52-wk High
$30.03
52-wk Low
$9.48

Latest Key Developments (Source: Significant Developments)

Nucana Announces Promising Clinical Data On Nuc-1031 As Front-Line Treatment Of Advanced Biliary Tract Cancer
Friday, 19 Jan 2018 

Jan 19 (Reuters) - Nucana Plc ::NUCANA ANNOUNCES PROMISING CLINICAL DATA AT ASCO GI ON NUC-1031 (ACELARIN®) AS FRONT-LINE TREATMENT OF ADVANCED BILIARY TRACT CANCER.NUCANA SAYS COMBINATION OF ACELARIN AND CISPLATIN WAS WELL-TOLERATED WITH NO UNEXPECTED ADVERSE EVENTS AND NO DOSE-LIMITING TOXICITIES.NUCANA PLC - IN TRIAL, 2 OF 8 PATIENTS RECEIVED ONLY ONE CYCLE OR LESS OF THERAPY DUE TO COMPLICATIONS UNRELATED TO EITHER ACELARIN OR CISPLATIN.NUCANA SAYS PLAN TO INITIATE PIVOTAL STUDY OF ACELARIN AND CISPLATIN IN FRONT-LINE ADVANCED BILIARY TRACT CANCER IN 2018.NUCANA PLC - ANALYSIS OF PHASE 1B STUDY SHOWED ACELARIN, WHEN COMBINED WITH CISPLATIN WAS WELL-TOLERATED IN FRONT-LINE ADVANCED BILIARY TRACT CANCER.NUCANA-STUDY SHOWED ACELARIN, WHEN COMBINED WITH CISPLATIN, ACHIEVED HIGH RESPONSE RATES, WAS WELL-TOLERATED IN FRONT-LINE ADVANCED BILIARY TRACT CANCER.  Full Article

NuCana Plc prices initial public offering of 6.7 mln American Depositary Shares at $15 per ADS
Thursday, 28 Sep 2017 

Sept 27 (Reuters) - Nucana Plc - :NuCana Plc announces pricing of initial public offering.Pricing of initial public offering of 6.7 million American Depositary Shares at price of $15 per ADS, for total gross proceeds of about $100 million.  Full Article

BRIEF-Nucana Announces Promising Clinical Data On Nuc-1031 As Front-Line Treatment Of Advanced Biliary Tract Cancer

* NUCANA ANNOUNCES PROMISING CLINICAL DATA AT ASCO GI ON NUC-1031 (ACELARIN®) AS FRONT-LINE TREATMENT OF ADVANCED BILIARY TRACT CANCER